OAC
RANI icon

OMERS Administration Corp’s Rani Therapeutics RANI Stock Holding History

OMERS Administration Corp’s Portfolio RANI Stock Details RANI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$56.2K Buy
76,500
+7,300
+11% +$9.33K ﹤0.01% 1057
2025
Q4 		$93.4K Buy
+69,200
New +$104K ﹤0.01% 974

Other funds holding RANI

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SCP
SymBiosis Capital Partners Bentonville, Arkansas $52.8M AUM
LP
Longaeva Partners Chicago, Illinois $2.7B AUM 37.16% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NFGH
Nan Fung Group Holdings Kai Tak, Hong Kong $121M AUM 56.89% 1-Year Est. Return

OMERS Administration Corp's RANI Position: Q1 2026 in Review

OMERS Administration Corp increased its Rani Therapeutics (RANI) stake by 11% in Q1 2026, buying an estimated $9.33K and bringing the position to 76,500 shares worth $56.2K. The position accounts for ﹤0.01% of the portfolio, ranked #1057.

OMERS Administration Corp first reported a position in RANI in Q4 2025 and has held it in 2 quarters since. The position peaked at $93.4K in Q4 2025. 74 funds tracked by Wall St. Rank hold RANI as of Q1 2026.

  • OMERS Administration Corp held 76,500 shares of Rani Therapeutics worth $56.2K as of Q1 2026.
  • OMERS Administration Corp bought 7,300 Rani Therapeutics shares in Q1 2026, an estimated $9.33K.
  • Rani Therapeutics made up ﹤0.01% of OMERS Administration Corp's portfolio in Q1 2026, its #1057 holding.
  • OMERS Administration Corp first reported a position in Rani Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • OMERS Administration Corp's Rani Therapeutics position peaked at $93.4K in Q4 2025.
  • 74 funds tracked by Wall St. Rank held Rani Therapeutics as of Q1 2026.

Based on OMERS Administration Corp's 13F filing for Q1 2026, filed 15 May 2026.